These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30051268)

  • 1. Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models.
    Hatswell AJ; Bullement A; Briggs A; Paulden M; Stevenson MD
    Pharmacoeconomics; 2018 Dec; 36(12):1421-1426. PubMed ID: 30051268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calibrating models in economic evaluation: a comparison of alternative measures of goodness of fit, parameter search strategies and convergence criteria.
    Karnon J; Vanni T
    Pharmacoeconomics; 2011 Jan; 29(1):51-62. PubMed ID: 21142278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of two methods for expert elicitation in health technology assessments.
    Grigore B; Peters J; Hyde C; Stein K
    BMC Med Res Methodol; 2016 Jul; 16():85. PubMed ID: 27456844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
    Andronis L; Barton P; Bryan S
    Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
    Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
    Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probabilistic analysis and computationally expensive models: Necessary and required?
    Griffin S; Claxton K; Hawkins N; Sculpher M
    Value Health; 2006; 9(4):244-52. PubMed ID: 16903994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis.
    Ren S; Minton J; Whyte S; Latimer NR; Stevenson M
    Pharmacoeconomics; 2018 Mar; 36(3):341-347. PubMed ID: 29081060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA.
    O'Hagan A; Stevenson M; Madan J
    Health Econ; 2007 Oct; 16(10):1009-23. PubMed ID: 17173339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models.
    Degeling K; IJzerman MJ; Koopman M; Koffijberg H
    BMC Med Res Methodol; 2017 Dec; 17(1):170. PubMed ID: 29246192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the expected rewards between probabilistic and deterministic analyses in a Markov model.
    Xie X; Yeung MW; Wang Z; Wang M; Gajic-Veljanoski O; Ng V; Volodin A
    Expert Rev Pharmacoecon Outcomes Res; 2020 Apr; 20(2):169-175. PubMed ID: 31116609
    [No Abstract]   [Full Text] [Related]  

  • 11. Regarding probabilistic analysis and computationally expensive models: necessary and required?
    Caro JJ; Getsios D; Möller J
    Value Health; 2007; 10(4):317-8; author reply 319. PubMed ID: 17645686
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of probabilistic decision models in technology assessment : the case of total hip replacement.
    Briggs A; Sculpher M; Dawson J; Fitzpatrick R; Murray D; Malchau H
    Appl Health Econ Health Policy; 2004; 3(2):79-89. PubMed ID: 15702945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Informing Reimbursement Decisions Using Cost-Effectiveness Modelling: A Guide to the Process of Generating Elicited Priors to Capture Model Uncertainties.
    Bojke L; Grigore B; Jankovic D; Peters J; Soares M; Stein K
    Pharmacoeconomics; 2017 Sep; 35(9):867-877. PubMed ID: 28616775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Handling uncertainty in cost-effectiveness models.
    Briggs AH
    Pharmacoeconomics; 2000 May; 17(5):479-500. PubMed ID: 10977389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence synthesis for decision making 6: embedding evidence synthesis in probabilistic cost-effectiveness analysis.
    Dias S; Sutton AJ; Welton NJ; Ades AE
    Med Decis Making; 2013 Jul; 33(5):671-8. PubMed ID: 23804510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Handling uncertainty of the economic evaluation result: sensitivity analysis.
    Limwattananon S
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S59-65. PubMed ID: 19253488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model Structuring for Economic Evaluations of New Health Technologies.
    Haji Ali Afzali H; Bojke L; Karnon J
    Pharmacoeconomics; 2018 Nov; 36(11):1309-1319. PubMed ID: 30030816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivariable and Structural Uncertainty Analyses for Cost-Effectiveness Estimates: Back to the Future.
    Mauskopf J
    Value Health; 2019 May; 22(5):570-574. PubMed ID: 31104736
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.